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Transient receptor potential melastatin member 4 (TRPM4), a non-selective cation
channel, mediates cell membrane depolarization in immune response, insulin secretion,
neurological disorders, and cancer. Pathological variants in TRPM4 gene have been
linked to several cardiac phenotypes such as complete heart block (CHB), ventricular
tachycardia, and Brugada syndrome (BrS). Despite recent findings regarding the
functional implications of TRPM4 in cardiac diseases, the molecular and cellular
mechanisms leading to altered conduction are poorly understood. In the present study,
we identify and characterize four novel TRPM4 variants found in patients with CHB
or ventricular fibrillation. Three of them, p.A101T, p.S1044C and a double variant
p.A101T/P1204L, led to a decreased expression and function of the channel. On the
contrary, the variant p.Q854R showed an increase in TRPM4 current. Recent evidence
indicates that altered degradation rate of mutant proteins represents a pathogenic
mechanism underlying genetic diseases. In consequence, protein turnover of WT-TRPM4
and TRPM4 variants overexpressed in HEK293 cells was analyzed using cycloheximide,
an inhibitor of protein biosynthesis. Upon addition of cycloheximide, WT-TRPM4 decayed
with a half-life of ∼20 h, while loss-of-expression variants showed a ∼30% increase in
degradation rate, with a half-life close to 12 h. Together, the gain-of-expression variant
showed a higher stability and a doubled half-life compared to WT-TRPM4. In conclusion,
decreased or increased protein expression of several TRPM4 variants linked to cardiac
conduction disorders or ventricular arrhythmias were found to be caused by altered
TRPM4 half-life compared to the WT form.
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INTRODUCTION
The transient receptor potential melastatin 4 (TRPM4) protein is an intracellular Ca2+ -
activated non-selective cation channel, which is impermeable to Ca2+. TRPM4 exhibits a voltage
dependence, which has not been previously described for any TRP channel, indicating that TRPM4
is both a Ca2+-activated and voltage-modulated cation channel (Nilius et al., 2005). At negative
membrane potentials, TRPM4 allows Na+ entry into the cell, leading to cellular membrane
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depolarization. At positive membrane potentials, TRPM4
channels permit cellular K+ eﬄux, leading to membrane
repolarization (Launay et al., 2002; Ramsey et al., 2006). TRPM4
is widely expressed in several tissues and is involved in a variety
of physiological processes, including modulation of immune cells
activity, such as T-cells (Launay et al., 2004), mast cells (Shimizu
et al., 2009) and dendritic cells (Barbet et al., 2010), insulin
secretion by pancreatic β cells (Cheng et al., 2007), mechano-
transduction in cerebral arteries (Vennekens and Nilius, 2007),
and Ca2+ signaling in cancer (Sozucan et al., 2015; Ceylan et al.,
2016; Sagredo et al., 2017). In addition, TRPM4 has been linked to
several neurological disorders such as experimental autoimmune
encephalomyelitis and multiple sclerosis (Schattling et al., 2012),
spinal cord injuries (Gerzanich et al., 2009), and traumatic
brain injuries (Simard et al., 2010). TRPM4 was reported to
participate in electrical perturbations following cardiac ischemia
and reperfusion episodes because of its sensitivity to Ca2+ and
ATP (Kalogeris et al., 2012). It has been shown that in a model
of hypoxia-reoxygenation using isolated mouse interventricular
septum, TRPM4 inhibitors 9-phenantrol and flufenamic acid
reduced [Ca2+]i overload, thus reducing the so called early
afterdepolarization (EAD) (Simard et al., 2012). However, the
physiological role for this channel in cardiac function remains
unclear. Recent studies have linked genetic variants of TRPM4
gene to progressive familial heart block type 1 (PFHB1) (Kruse
et al., 2009; Daumy et al., 2016), isolated cardiac conduction
disease (ICCD) (Liu et al., 2010), atrio-ventricular block (AVB)
(Stallmeyer et al., 2012; Syam et al., 2016), right bundle branch
block (RBBB) (Stallmeyer et al., 2012) and Brugada syndrome
(BrS) (Liu et al., 2013; Gualandi et al., 2017). Several TRPM4
variants linked to inherited cardiac diseases were shown to cause
either gain- or loss-of-function of the channel activity. However,
the molecular details of these alterations, and how both gain- and
loss-of-function variants may lead to conduction defects remains
poorly understood.
In the present study, we identified four novel TRPM4 genetic
variants found in patients with either complete heart block
(CHB) or idiopathic ventricular fibrillation (IVF). Biochemical
and functional characterizations of these variants identified three
with loss-of-function and one with gain-of-function. We further
examined the possible mechanisms leading to altered protein
stability using cycloheximide, an inhibitor of protein synthesis.
Our results revealed an altered protein turnover in loss- and
gain-of-expression mutant compared to theWT form of TRPM4,
showing that altered half-life of TRPM4 is one of the mechanisms
leading to several cardiac conduction disorders.
MATERIALS AND METHODS
Patient Genetic Screening
The study was conducted according to the Swiss and Canadian
guidelines for genetic research and approved by the ethics
committees of University Hospital Bern and the University of
Ottawa Heart Institute respectively. All subjects gave written
informed consent in accordance with the Declaration of Helsinki.
Genomic DNA was isolated from peripheral macrophages by
standard procedures using Gentra Puregene Blood kit (Qiagen,
Hilden, Germany). A targeted exome panel sequencing was
performed by Next Generation Sequencing using the TrueSight
One Sequencing Panel (Illumina, SanDiego, CA, USA). Sequence
data were compared with the reference sequence of the
human TRPM4 gene (MIM# 606936; RefSeq NM_017636.3;
Ensembl gene reference: ENSG00000130529, referring to isoform
TRPM4b).
Generation of TRPM4 Mutants
The complete human wild-type HA-tagged TRPM4 cDNA was
cloned in a pcDNA4/TO vector. Mutants were obtained by
in vitro mutagenesis using Q5 Site-Directed Mutagenesis kit
(New England Biolabs, Ipswich,MA, USA).Mutant cDNA clones
were then sequenced before using them in experiments.
Cell Culture and Transfection
Human embryonic kidney (HEK293) cells were cultured with
Dulbecco’s modified Eagle’s culture medium supplemented with
4mM Glutamine, 10% FBS and a cocktail of streptomycin-
penicillin antibiotics. For the electrophysiological studies, the
cells were transiently transfected with 240 ng of HA-TRPM4
WT or HA-TRPM4 p.A101T, HA-TRPM4 p.Q854R, HA-TRPM4
p.S1044C, HA-TRPM4 p.P1204L, and double variant HA-
TRPM4 p.A101T/P1204L in a 35mm dish (BD Falcon, Durham,
North Carolina, USA) mixed with 4 µL of JetPEI (Polyplus
transfection, Illkirch, France) and 46 µL of 150mM NaCl.
The cells were incubated for 24 h at 37◦C with 5% CO2. All
transfections included 100 ng of eGFP as a reporter gene.
Expression of GFP was used to identify transfected cells, for patch
clamp experiments.
For the biochemical experiments, HEK293 cells were
transiently transfected with 240 ng of either HA-TRPM4 WT,
or HA-TRPM4 p.A101T, HA-TRPM4 p.Q854R, HA-TRPM4
p.S1044C, HA-TRPM4 p.P1204L, and double variant HA-
TRPM4 p.A101T/P1204L, or empty vector (pcDNA4TO) in a
P100 dish (BD Falcon, Durham, North Carolina, USA) mixed
with 30 µL of JetPEI (Polyplus transfection, Illkirch, France) and
250 µL of 150mM NaCl. The cells were incubated for 48 h at
37◦C with 5% CO2.
Cell Surface Biotinylation Assay
Following 48 h of incubation, transiently transfected HEK293
cells, previously washed twice with cold 1X PBS, were
treated with EZlinkTM Sulfo-NHS-SS-Biotin (Thermo Scientific,
Waltham, MA, USA) 0.5 mg/mL in cold 1X PBS for 15min at
4◦C. Subsequently, the cells were washed twice with 200mM
Glycine in cold 1X PBS and twice with cold 1X PBS to inactivate
and remove the excess biotin, respectively. The cells were then
lysed with 1X lysis buffer [50mM HEPES pH 7.4; 150mM
NaCl; 1.5mM MgCl2; 1mM EGTA pH 8.0; 10% Glycerol;
1% Triton X-100; 1X Complete Protease Inhibitor Cocktail
(Roche, Mannheim, Germany)] for 1 h at 4◦C. Cell lysates were
centrifuged at 16,000 g at 4◦C for 15min. Two milligrams of the
supernatant were incubated with 50 µL Streptavidin Sepharose
High Performance beads (GE Healthcare, Uppsala, Sweden) for
2 h at 4◦C, and the remaining supernatant was kept as the input.
The beads were subsequently washed five times with 1X lysis
buffer before elution with 50 µL of 2X NuPAGE sample buffer
(Invitrogen, Carlsbad, CA, USA) plus 100mM DTT at 37◦C for
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30min. These biotinylated fractions were analyzed as TRPM4
expressed at the cell surface. The input fractions, analyzed as
total expression of TRPM4, were resuspended with 4X NuPAGE
Sample Buffer plus 100mM DTT to give a concentration of 1
mg/mL and incubated at 37◦C for 30min.
Western Blot Experiments
Protein samples were analyzed on 9% polyacrylamide gels,
transferred with the TurboBlot dry blot system (Biorad,
Hercules, CA, USA) and detected with anti-TRPM4 (generated
by Pineda, Berlin, Germany), anti α-actin A2066 (Sigma-
Aldrich, St. Louis, MO, USA), anti-alpha Na+/K+ ATPase α1
ab7671 (Abcam, Cambridge, UK) antibodies using SNAP i.d.
(Millipore, Billerica, MA, USA). The anti-TRPM4 antibody was
generated by Pineda (Berlin, Germany) using the following
peptide sequence: NH2-CRDKRESDSERLKRTSQKV-CONH2.
A fraction of the antisera, which was subsequently used in this
study, was affinity purified. Actin and alpha-Na+/K+ ATPase
were used to normalize TRPM4 protein band intensity in total
fraction and surface fraction respectively. Original Western blot
pictures of the three replicates for total and surface fractions
were shown in Supplementary Figures 1, 9, and 11 for total
expression, and Supplementary Figures 2, 10 and 12 for surface
expression. A summary of raw WB picture was also submitted
as Supplementary Figure 13. All the Western Blots have been
quantified using Image Studio Lite software from LI-COR
Biosciences (Lincoln, NE, USA).
Immunoprecipitation and Protein Half-Life
Determination Experiments
For half-life experiments, HEK 293 transiently transfected cells
were treated with 100µg/mL cycloheximide (Millipore, Billerica,
MA, USA) or 0,3% DMSO as control and lysed at various time
points using 1X UBI buffer [50mM HEPES pH 7.4, 150mM
NaCl, 1mM EGTA pH 8.0, 10% Glycerol, 1% Triton X-100,
1X Complete Protease Inhibitor Cocktail EDTA-free (Roche,
Mannheim, Germany)]. Two milligrams of protein lysate were
incubated overnight with 20 µg of anti-TRPM4 antibody in a
final volume of 1mL. The lysate-antibody was then transferred
on Protein G Sepharose 4 Fast Flow beads (GE Healthcare,
Uppsala, Sweden) and rotated overnight at 4◦C. Beads were
washed 5 times with 1X UBI buffer with 0.5% Triton before
elution with 50 µL of 2X NuPAGE sample buffer (Invitrogen,
Carlsbad, CA, USA) plus 100mM DTT at 37◦C for 30min.
Samples were loaded on a 9% polyacrylamide gel and TRPM4
expression was revealed using anti-HA antibody (Enzo Life
Sciences, Lausen, Switzerland). Original Western blot pictures
are shown in Supplementary data (Supplementary Figures 3–8).
To extrapolate the half-life of WT-TRPM4 and TRPM4 variants,
the relative protein band intensity was fitted with mono-
exponential function, and time for 50% decay of intensity was
estimated.
Quantitative Real Time PCR
Total RNA isolation was performed using TRIzol Reagent
(Applied Biosystems, Foster City, CA, USA) as described by
the manufacturer. Concentration and purity of total RNA was
determined by optical density measurement using a NanoDrop
2000 spectrophotometer (Thermo Scientific, Waltham, MA,
USA). cDNA was synthesized using High Capacity cDNA
Reverse Transcription kit (Applied Biosystems, Foster City,
CA, USA) and quantitative expression analysis was performed
with 7500 Fast Real-Time PCR System (Applied Biosystems,
Foster City, CA, USA). Quantification of mRNA expression
levels was investigated with TaqMan gene expression assay
Hs00214167_m1 for human TRPM4, using GAPDH TaqMan
gene expression assay Hs02758991_g1 as a control. Relative
expression of the studied gene was calculated with the 2−11Ct
method.
Cellular Electrophysiology
Electrophysiological recordings were performed in the inside-
out patch clamp configuration with patch pipettes (1–2µm tip
opening) pulled from 1.5mm borosilicate glass capillaries (Zeitz-
Instruments, GmbH, München, Germany) using micropipette
puller P 97 (Sutter Instruments, Novato, CA, USA). The tips
were polished to have a pipette resistance of 2–4 M in the
bath solution. The pipette solution contained (in mM) 150
NaCl, 10 HEPES, and 2 CaCl2 (pH 7.4 with NaOH). The
bath solution contained (in mM) 150 NaCl 10 HEPES, 2
HEDTA (pH 7.4 with NaOH) as 0 Ca2+ solution. Solutions
containing 300µM Ca2+ were made by adding the appropriate
concentration of CaCl2 without buffer to a solution containing
(in mM) 150 NaCl, 10 HEPES (pH 7.4 with NaOH) as
reported previously (Zhang et al., 2005). Bath solution with
0 and 300µM Ca2+ concentrations were applied to cells by
a modified rapid solution exchanger (Perfusion Fast-Step SF-
77B; Warner Instruments Corp., CT, USA). Membrane currents
were recorded with a Multiclamp 700B amplifier (Molecular
Devices, Sunnyvale CA, USA) controlled by Clampex 10 via
a Digidata 1332A (Molecular Devices, Sunnyvale, CA, USA).
Data were low-pass filtered at 5 kHz and sampled at 10 kHz.
Experiments were performed at room temperature (20–25◦C).
For measuring steady state currents, stimulation protocol
consisted of a single 200ms voltage step to −100 and then
to+100mV.
Statistical Analysis
Data are represented as the mean ± s.e.m. One-way ANOVA
followed by Sidak’s multiple comparison test was used to
compare the samples, with a p < 0.05 considered as significant.
Electrophysiology data were exported and analyzed using IGOR
PRO 6 (Wavematrix, London, UK).
RESULTS
Patients Information
In the present study, we performed genetic analysis of the TRPM4
gene in patients to elucidate its role in various types of cardiac
conduction disorders or ventricular arrhythmias. The clinical
details of the variant carriers are presented in Table 1 and the
electrocardiogram (ECG) recordings are shown in Figure 1. In
Ottawa Heart Institute, 26 patients with premature heart block
(age <60 years) were screened. Together, 100 patients from
an elderly (age > 70 years) control population were screened
for the identified rare variants. In Bern, the TRPM4 gene is
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TABLE 1 | Patients characteristics.
Patient ID Protein Sex Age at diagnosis (years) Circumstances of discovery Family history Phenotype
1 p.A101T Male 54 Dizziness No CHB
1A p.A101T Male 71 Asymptomatic No cRBBB
2 p.Q854R Female 53 Syncope Unknown CHB
3 p.S1044C Female 48 Syncope Mother had PM (deceased) CHB
4 p.A101T/P1204L Female 17 Resuscitated SCD Yes IVF
CHB, complete heart block; cRBBB, complete right bundle branch block; PM, pacemaker; SCD, sudden cardiac death; IVF, idiopathic ventricular fibrillation.
screened routinely in cases with suspected channelopathies. In
these cohorts, four novel TRPM4 variants leading to cardiac
disorders were identified (Figure 1A). The p.A101T variant
was found in a 54 years old male with dizziness, who was
diagnosed with CHB (Figure 1B). The same variant was also
found in an asymptomatic control patient who was subsequently
identified to have a complete RBBB on ECG. Other variants
in the control patient were absent (Table 1). The p.Q854R
and p.S1044C variants were found in two female patients with
syncope and an ECG presentation of CHB at 53 and 48 years
of age respectively. The mother of the 48 years old patient also
had a pacemaker (Table 1). The missense p.A101T mutation was
also found, together with a p.P1204L mutation, in a 17 years
old patient from the University Hospital Bern who had sudden
cardiac death. This patient had exhibited frequent monomorphic
premature ventricular beats during exercise prior to her sudden
cardiac death (SCD) event (Figures 1C,D). She had history of
recurrent syncope since she was 14 years old. ECG and magnetic
resonance imaging (MRI) were normal. This patient had also a
novel homozygous mutation in ryanodine receptor 2 (RYR2) in
position c.365G>A (p.R122H), but no clear Catecholaminergic
Polymorphic Ventricular Tachycardia (CPVT) was observed.
Relatives have been tested for the three mutations: both parents
are heterozygous for RYR2-R122H, and the mother is carrier
of both TRPM4 mutations. Both parents are asymptomatic and
exhibit no obvious cardiac pathological phenotype. Given the
uncertainty of the causative genotype, p.P1204L has been also
investigated as a single variant, but was already reported to
be implicated in cardiac conduction disturbances and/or BrS
(Stallmeyer et al., 2012; Liu et al., 2013). To predict the impact of
the amino acid substitution, exome variant server (http://evs.gs.
washington.edu/EVS/), as well as Polyphen2, SIFT and Mutation
Taster were used (Table 2). For data interpretation, human gene
mutation database (HGMD, Biobase), 1000 genoms and ExAC
browser were used.
TRPM4 Variants Expression Pattern
To understand the consequences of the four novel mutations
on the TRPM4 channel, we analyzed total expression of TRPM4
after transient transfection of HEK293 cells and its expression at
the cell surface by Western Blot and cell surface biotinylation
experiments. As previously reported (Syam et al., 2014), we
observed that the TRPM4 channel is expressed in fully and
core glycosylated forms. As shown in Figure 2, we observed a
50% reduction in the total expression of p.A101T and p.S1044C,
when compared to the WT TRPM4, both in fully and in core
glycosylated bands (Figures 2A–C). p.P1204L and the double
variant p.A101T/P1204L showed a more severe reduction in
the total expression, in both fully and core glycosylated bands
(70 and 75% respectively), when compared to WT TRPM4
(Figures 2A–C). The decrease in TRPM4 expression was more
pronounced at the cell surface for all the loss-of-expression
variants (70% loss for p.A101T and p.A101T/P1204L, 60% loss
for p.S1044C, 80% loss for p.P1204L), for both fully and core
glycosylated bands (Figures 2B–D). On the other hand, p.Q854R
showed an increased protein expression in both fully and core
glycosylated bands of total and surface expression (130 and 110%
respectively) (Figures 2B–D). However, these increases were not
statistically significant. We then performed quantitative Real-
Time PCR experiments to determine whether these differences
in protein expression may have been due to variable mRNA
levels after transient transfection. No significant differences
were observed in mRNA expression among the variants when
compared to WT TRPM4 gene (Figure 3).
Functional Analysis
To determine possible functional alterations caused by these
variants, macro-patch current recordings were performed
using inside-out patch clamp on HEK293 cells expressing
WT TRPM4 or p.A101T, p.Q854R, p.S1044C, p.P1204L, and
p.A101T/P1204L. Figure 4 shows that a 200ms voltage step
from −100 to +100mV from a holding voltage of 0mV elicited
small outward Na+ currents when exposed to nominally 0 Ca2+
bath solution (39.6 ± 9.5 pA), whereas it induced large outward
currents in presence of 300µM Ca2+ (4768.7 ± 574.6 pA). The
amplitude of outward current measured at the end of voltage step
to +100mV varied among the variants. In line with the western
blot data (Figure 2), variants p.A101T (249.7 ± 44.5 pA, n = 7),
p.S1044C (314 ± 95.4 pA, n = 6), p.P1204L (248.7 ± 82.9 pA, n
= 7), and double variant p.A101T/P1204L (142.6 ± 27.7 pA, n
= 11) showed reduced current while the variant p.Q854R (8735
± 637.7 pA, n = 7) showed increased outward current when
compared to WT (4768.7± 574.6 pA, n= 13; Figure 4B).
Half-Life of WT-TRPM4 and TRPM4
Variants
To understand the cellular mechanism leading to loss- or
gain-of-expression in TRPM4 variants, the half-life of WT
and mutated TRPM4 was analyzed using the protein synthesis
blocker cycloheximide. Approximately 24 h after transfection,
transiently transfected HEK293 cells were incubated with
100µg/mL cycloheximide and harvested prior to inhibition (0 h)
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FIGURE 1 | ECG recordings and variants information. (A) Variants location in the TRPM4 protein. (B) ECG from patient 1 carrying p.A101T variant and showing a
complete heart block phenotype. (C,D) ECG from patient 5 carrying p.A101T/P1204L variant at rest (C) and under physical exercise showing IVF phenotype (D). The
arrowhead shows the administration of beta-blockers.
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TABLE 2 | Variants characteristics.
Patient
ID
cDNA Exon Protein Predicted protein localization GVS function EVS Eur-Am PolyPhen-2 analysis
1 c.301G>A 3 p.A101T N-terminal, cytoplasmic Missense A = 161/G = 8439 Benign (Score:0.000)
2 c.2561A>G 17 p.Q854R Cytoplasmic Missense G = 10/A = 8550 Benign (Score:0.008)
3 c.3130A>T 20 p.S1044C Helical n.d. N.P n.d.
4 c.3611C>T 23 p.P1204L C-terminal, cytoplasmic Missense T = 28/C = 8542 Possibly damaging
(Score:0.008)
4 c.301G>A; c.3611C>T 3;23 p.A101T/P1204L N-terminal, C-terminal, cytoplasmic n.d. N.P n.d.
EVS Eur-Am, Exome Variant Server European-American Population; GVS, Genome Variation Server; N.P., not present in Exome Variant Server; n.d., not determined.
FIGURE 2 | Western Blot analysis of HEK293 cells transiently expressing WT-TRPM4 and TRPM4 variants. Representative immunoblots of human TRPM4 expression
at the total (A) and surface expression (B). Actin and alpha Na+/K+ ATPase were used for normalization of the total and the surface expression respectively. White
and black arrowheads represent fully and core glycosylated band respectively. Quantification of the total expression (C) and surface expression (D) is shown as
relative intensity of protein band for both full and core glycosylated forms of TRPM4 in each fraction. Data are represented as mean ± s.e.m. of n = 3; *P < 0.05;
**P < 0.005; ***P < 0.001.
and at 4, 16, 24, and 36 h post-treatment using a TRPM4
immunoprecipitation protocol. For each time point, a 0.3%
DMSO control was used to normalize TRPM4 expression.
The observed pattern of WT-TRPM4 protein expressed over
time following cycloheximide treatment (Figure 5) provided
a half-life of ∼18 h for the fully glycosylated form, and
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FIGURE 3 | mRNA TRPM4 expression of WT and variants. qPCR analysis on
TRPM4 gene expression in HEK 293 cells transiently transfected with
WT-TRPM4 and TRPM4 variants. Data are represented as relative mRNA
expression. The expression of GAPDH is used as reference (mean ± s.e.m. of
n = 6). No significant differences are observed between WT and variants.
30 h for the core glycosylated form (Figure 6 and Table 3).
Interestingly, in presence of cycloheximide we observed a
more rapid decay in TRPM4 expression of all loss-of-
expression variants, with a half-life of ∼12 h for p.A101T,
p.S1044C and the double variant p.A101T/P1204L, for both
fully and core glycosylated fractions (Figures 5, 6 and Table 3).
p.P1204L was even more rapidly degraded, and the signal
was only partially detectable after 10 h incubation, leading to
a half-life of both fully and core glycosylated band of ∼8 h
(Figure 6 and Table 3). Under the same conditions, gain-
of-expression p.Q854R variant half-life has been estimated,
resulting to exceed 24 h, and reaching 50 h in both fully
and core glycosylated band (Figure 6 and Table 3). Taken
together, these experiments indicate that the difference in plasma
membrane expression of WT-TRPM4 and TRPM4 variants
reflects different degradation kinetics, which causes variations in
protein expression.
DISCUSSION
In the present study, four novel TRPM4 variants have been
identified in patients with CHB and IVF. Biochemical and
electrophysiological studies revealed a reduced protein
expression and function for p.A101T, p.S1044C, and
p.A101T/P1204L compared to WT, while p.Q854R showed
an increased TRPM4-mediated current. Furthermore, we
observed that, when expressed in HEK293 cells, these variant
TRPM4 proteins had either increased or decreased degradation
rates when compared to WT protein.
The underlying mechanisms leading to conduction defects
caused by TRPM4 mutations are not yet understood. Moreover,
in this work, both gain and loss of function variants led to the
same pathology. A similar observation was made in a series
FIGURE 4 | Inside-out patch clamp recordings of WT and TRPM4 variants.
(A) Individual current traces of WT TRPM4 and TRPM4 variants after applying
300µM Ca2+. (B) Quantification of currents of WT and cardiac conduction
disorders variants. **P < 0.005; ***P < 0.001 (WT, n = 13; A101T, n = 7;
Q854R, n = 7; S1044C, n = 6; P1204L, n = 7; A101T/P1204L, n = 11).
of Brugada cases with mutations in the TRPM4 channel (Liu
et al., 2013) and in another series of patients with congenital or
childhood atrioventricular block (Syam et al., 2016). While it
may seem paradoxical that both gain- and loss-of-function can
lead to similar phenotype, one may propose that, if TRPM4 is
influencing the restingmembrane potential of conduction system
cells, both membrane hyperpolarization and depolarization will
cause conduction slowing (Abriel et al., 2012), in analogy to
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FIGURE 5 | Half-life of WT and TRPM4 variants. Immunoblots showing immunoprecipitation with anti-TRPM4 antibody. Cells were harvested prior to treatment (0 h)
and 4, 16, 24, and 36 h after treatment with 100µg/ml cycloheximide. TRPM4 is detected using anti-HA antibody in presence of 100µg/ml cycloheximide (left panel),
or 0.3% DMSO (right panel). White and black arrowheads represent fully and core glycosylated band respectively. Data are representative of three independent
experiments.
the supernormal conduction phenomenon which has been
described in atrioventricular conduction (Moore et al., 1993).
However, to date, there is no report demonstrating a direct
role of TRPM4 in this phenomenon, hence motivating further
investigation on the role of TRPM4 in the conduction pathway
(Mathar et al., 2014). The presence of a TRPM4 loss-of-function
variant in a case with IVF is intriguing and we can thus far only
speculate that its possible consequences on impulse propagation
may exacerbate the arrhythmogenic potential of the observed
RYR2 mutation. It is however impossible to exclude that this
presents a variant with no direct functional consequences in
vivo. A recent report investigated the involvement of TRPM4 in
conduction block and arrhythmic phenomena associated with
cardiac remodeling and injury, showing that TRPM4 channel is
activated by a physiological range of Ca2+ concentrations and
that its excessive activity can cause arrhythmic changes (Hu
et al., 2017). In mouse ventricles, a negative impact of TRPM4
channel activity on cardiac contractility despite action potential
prolongation has been proposed, and this mechanism was found
to be suppressed in TRPM4 KO mice (Mathar et al., 2014).
Further improvement of action potential models may help to
understand more complex mechanisms underlying arrhythmias
and conduction failures associated with TRPM4 genetic
mutations.
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FIGURE 6 | TRPM4 protein expression decay. Immunoblots from Figure 5 are
quantified as relative intensity of protein band of the fully (A) and the core (B)
glycosylated band. 0.3% DMSO values are used at each time point for
normalization. Statistical analysis has been performed using one-way ANOVA
and results are shown in Supplementary Table 1.
Using cycloheximide, we investigated whether the variant-
induced altered expression of TRPM4 in HEK293 cells may
result from modified protein stability. TRPM4 half-lives of the
core and fully glycosylated fractions have been determined for
the WT and variant proteins causing conduction defects. Our
findings revealed that the fully and the core glycosylated fractions
of WT channels had half-lives of ∼20 and ∼30 h, respectively.
These values are in line with Woo and colleagues’ study, where
they observed a half-life of ∼24 h for WT mouse TRPM4
(Woo et al., 2013). Together, loss-of-expression mutants undergo
a more rapid degradation rate, resulting in reduced half-life
compared to WT. Interestingly, the mutation leading to gain-
of-expression significantly decreased the degradation rate of the
fully and core glycosylated fractions, with a half-life of ∼50 h. In
contrast, the loss-of-expression variant half-life alterations were
mainly seen in the core glycosylated fractions. These observation
are consistent with a model where the decrease and increase
of TRPM4 currents are due to changes in TRPM4 channel
TABLE 3 | Variants half-life values.
Variant Fully glycosylated band
half-life values (hours ±
s.e.m.)
Core glycosylated band
half-life values (hours ±
s.e.m.)
WT-TRPM4 17.4 ± 1.6 31.4 ± 2.6
p.A101T 10.5 ± 1.1 12.7 ± 1.2
p.Q854R 52.3 ± 6.8 53.8 ± 4.7
p.S1044C 10.1 ± 0.7 11.0 ± 0.6
p.P1204L 8.3 ± 0.6 9.9 ± 0.4
p.A101T/P1204L 13.0 ± 0.6 13.8 ± 0.4
densities at the plasma membrane caused by variant-induced
trafficking alterations. However, it is likely that the mechanisms
leading to the loss of expression are not the same as the one
underlying the gain of expression. It can be hypothesized that
the increased degradation rates of the core-glycosylated fractions
reflect misfolding of the nascent proteins and subsequent ER-
associated protein degradation (ERAD) (Meusser et al., 2005). In
a recent study (Syam et al., 2016), two loss-of-expression TRPM4
variants found in patients with congenital AVB were rescued
upon decreased incubation temperature for 24 h suggesting
that variant-induced misfolding of TRPM4 may be a common
molecular mechanism similar to the case of human ether-
a-go-go-related gene voltage-gated potassium channel Kv11.1
(Zhou et al., 1999). On the other hand, assuming that the
fully glycosylated TRPM4 fraction is predominant at the plasma
membrane, it can be speculated that the reduced degradation
of the p.Q854R variant reflects a decreased internalization rate
as proposed for other gain of function variants (Kruse et al.,
2009). Future experiments will have to be performed to assess this
hypothesis.
Ion channels, including many TRP channels, are subjected to
post-translational modifications which regulate their trafficking
and stability at the cell membrane. It has been reported that
human and mouse TRPM4 are N-linked glycosylated at a
unique residue, Asn992 and Asn988 respectively (Woo et al.,
2013; Syam et al., 2014). N-glycosylation has been found to
be crucial for surface expression of several TRP channels, but
most studies have been performed on heterologous systems,
with induced ion channels overexpression; therefore, native and
recombinant proteins may act differently due to differences
in in vivo glycosylation. Recent reports suggested the role
of SUMOylation as a possible post-translational modification
implicated in TRPM4 trafficking. Kruse and colleagues proposed
that the p.E7K TRPM4 mutation leading to a gain-of-function
and expression was subjected to an increased SUMOylation
which augments its membrane expression (Kruse et al.,
2009). In contrast, Syam et al. showed immunoprecipitation
experiments withWTTRPM4 and the gain-of-expression variant
p.G582S, where no direct SUMOylation of TRPM4 seemed
to be observed (Syam et al., 2016). Ubiquitination is another
frequent post-translational modification of ion channels. In
our previous work (Syam et al., 2016), we performed GST-
S5a pull down experiments to address whether ubiquitination
Frontiers in Physiology | www.frontiersin.org 9 March 2018 | Volume 9 | Article 177
Bianchi et al. TRPM4 Variants Stability
was involved in differences in expression and degradation
between WT and variants. Our findings revealed that the
difference in degradation rate of WT and mutants does not
depend on a different rate of ubiquitination. Based on these
contrasting results, the involvement of SUMOylation and/or
ubiquitination leading to increased TRPM4 expression in
patients with cardiac conduction disorders still remains to be
elucidated.
Recently, the electron cryo-microscopy structure of the
human TRPM4 has been reported (Winkler et al., 2017). It is
shown there that TRPM4 is composed by four cytosolic C-
terminal domains which form an umbrella-like structure, with
a coil domain for the “pole” and four N-terminal helical “ribs.”
p.A101T and p.P1204L are found in well conserved N-terminal
and C-terminal residues respectively, while p.Q854R is located
in the S2-S3 linker and does not seem to play a crucial role
in TRPM4 structure. Interestingly, p.S1044C has been identified
to be located in the intracellular gate and might play a role
in TRPM4 permeability to Na+ (Winkler et al., 2017). Further
studies would be required to assess S1044 specific role in the
channel function.
LIMITATIONS OF THE STUDY
The novel TRPM4 variants described in this work were not
assessed in terms of their intrinsic biophysical properties.
Further studies using cardiac cells instead of HEK 293 cells
may give additional information regarding their relevance
in action potential conduction and could lead to a better
understanding of the role of TRPM4 in cardiac conduction
disorders. In conclusion, although the molecular mechanism
underlying protein degradation dysfunctions and their role
in cardiac diseases are only beginning to be revealed, it
has become clear that altered protein degradation affecting
protein half-life may play an important role in a variety of
genetic cardiac disorders, including cardiac conduction defects in
presence of TRPM4 mutations. Further studies, using knock-in
mice or CRISPR/Cas9-dependent editing of human iPS-derived
cardiomyocytes, may help to develop clinically relevant strategies
to correct protein trafficking abnormalities, including misfolded
TRPM4 mutants in cardiac conduction phenotypes.
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